文献速递消化道肿瘤与早癌肝病

慢性肝病患者的结直肠癌风险:系统综述与荟萃分析

Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2016-12-21

该系统综述与荟萃分析共纳入50项研究、55,991例患者,评估慢性肝病患者结直肠癌风险。肝炎与肝硬化患者合并标准化发病比为2.06(95%CI 1.46-2.90),肝移植后患者为2.16(95%CI 1.59-2.94);原发性硬化性胆管炎患者合并标准化发病比为6.70(95%CI 3.48-12.91)。作者认为该人群结直肠癌风险升高,需更密集的监测。

要点

  • 慢性肝病患者结直肠癌风险较一般人群升高,合并标准化发病比2.06(95%CI 1.46-2.90)。
  • 肝移植后患者结直肠癌风险仍升高,合并标准化发病比2.16(95%CI 1.59-2.94)。
  • 原发性硬化性胆管炎患者结直肠癌风险升高更明显,合并标准化发病比6.70(95%CI 3.48-12.91)。

核心结论

  • 慢性肝病患者结直肠癌风险较一般人群升高,且肝移植后该风险持续存在。
  • 作者认为该人群需要更密集的结直肠癌监测。

研究设计与样本

  • 系统综述与荟萃分析,检索电子数据库评估慢性肝病患者结直肠癌风险的研究。
  • 共纳入50项研究、55,991例患者。
  • 主要结局为以标准化发病比(SIR)报告风险的研究的合并风险。

主要发现

  • 纳入肝炎与肝硬化患者的研究中,合并SIR为2.06(P < .0001;95%CI 1.46-2.90),异质性中等(I2 = 49.2%),异质性似源于疾病亚组间差异与研究把握度。
  • 3项研究报告原发性硬化性胆管炎患者结直肠癌风险升高,合并SIR为6.70(P < .0001;95%CI 3.48-12.91),异质性中等(I2 = 36.3%),异质性似源于研究把握度差异。
  • 纳入肝移植后患者的研究中,合并SIR为2.16(P < .0001;95%CI 1.59-2.94),异质性中等(I2 = 56.4%)。
  • 荟萃回归显示自身免疫相关肝病比例与结直肠癌风险之间存在相关性。

临床怎么用

  • 作者认为慢性肝病患者(包括肝移植后患者)需要更密集的结直肠癌监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The risk of colorectal cancer (CRC) in various chronic liver diseases compared with the general population remains unclear. We performed a systematic review and meta-analysis to assess the risk of CRC in patients with chronic liver diseases before and after liver transplantation. METHODS: Electronic databases were searched for studies assessing the risk of CRC in patients with chronic liver diseases. The primary outcome was the pooled risk of CRC among studies that reported the risk as standardized incidence rate (SIR). RESULTS: Fifty studies that included 55,991 patients were identified. Among studies that included hepatitis and cirrhotic patients, the pooled SIR was 2.06 (P < .0001; 95% confidence interval (CI), 1.46-2.90) with moderate heterogeneity (I2 = 49.2%), which appeared to be because of the difference between subgroup of diseases and the power of studies. Three studies reported an increased risk of CRC in primary sclerosing cholangitis patients (pooled SIR 6.70; P < .0001; 95% CI, 3.48-12.91) with moderate heterogeneity (I2 = 36.3%), which appeared to be because of the difference between the power of studies. Among studies that included post-transplant patients, the pooled SIR was 2.16 (P < .0001; 95% CI, 1.59-2.94) with moderate heterogeneity (I2 = 56.4%). Meta-regression showed a correlation between the proportion of autoimmune-related liver diseases and the risk of CRC. CONCLUSIONS: Patients with chronic liver diseases had an increased risk of CRC compared with the general population, which persisted after liver transplantation. A more intensive surveillance for CRC is warranted in this population.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Komaki Y, Komaki F, Micic D, et al. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 2016. PMID: 28011280. doi:10.1016/j.gie.2016.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。